Revolution Medicines Targets RAS | Business and Finance News

Revolution Medicines is shaking up cancer treatment by targeting the RAS protein to halt tumor growth in aggressive cancers like pancreatic, lung, and colorectal—potentially replacing brutal chemotherapy. Though not yet FDA-approved and revenue-free, early Phase Three data shows it nearly doubled survival in pancreatic cancer patients, earning fast-track designations from both the FDA and EMA. Backed by billionaire Stanley Druckenmiller’s major investment, the stock has surged 125% this year, reflecting high hopes for a global launch—if successful, this could redefine how tough cancers are treated. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/45e25cf189fb7089